Essentials
• Defective binding to collagen IV has been seen in von
Willebrand factor (VWF) A1 domain variants.
• We developed a murine model of defective VWF-collagen IV interactions with VWF variant p.R1399H.
• p.1399HH homozygous mice had decreased binding to collagen IV and increased bleeding times.
• p.1399HH homozygous mice had increased time to thrombosis and decreased platelet adhesion.
Summary. Background: von Willebrand factor (VWF) binding to type IV collagen occurs via the VWF A1 domain, with p.R1399H being the most common VWF variant affecting this interaction. Objectives: We generated a murine model of 1399H VWF to investigate its in vivo effects. Methods: Mice expressing the murine 1399H variant were generated via gene targeting in embryonic stem cells. VWF antigen and VWF collagen binding were measured with ELISA. Tail bleeding time assays were performed by clipping a 3-mm segment. Ferric chloride-induced thrombosis was measured via ultrasound in the carotid artery. Platelet aggregation in response to collagens I and IV was measured. VWFdependent platelet adhesion to collagen IV was measured under flow. Results: Breeding of heterozygous p.R1399H and homozygous p.1399HH mice was observed to follow normal Mendelian ratios. No spontaneous bleeding was observed for any of the offspring. VWF expression was normal, but VWF binding to collagen IV was decreased in both heterozygous and homozygous offspring. Blood loss following tail resection was increased for p.1399HH mice, and occlusion times following ferric chlorideinduced thrombosis were prolonged. Platelet aggregation was unaffected, but platelet adhesion to collagen IV under flow was diminished for p.1399HH mice. Conclusions: These results show that a decrease in the ability of 1399H VWF to bind collagen IV under static conditions corresponds to a decrease in binding under flow conditions, an increased bleeding time, and a prolonged time to thrombosis. This study supports the potential for a bleeding phenotype in patients
Introduction
Although von Willebrand factor (VWF) is most well known for its functions in platelet binding and factor VIII binding, it also binds to collagen at sites of injury. Binding sites on VWF for vascular collagens are located in the VWF A1 and A3 domains. Both type I and type III collagen bind VWF via the A3 domain [1] , whereas type IV and type VI collagen bind VWF via the A1 domain [2, 3] . Testing for von Willebrand disease (VWD) generally involves assays that examine platelet binding, although collagen binding may provide additional useful information. Defects in VWF lead to VWD, most commonly through reduced protein levels or an absence of total protein seen in types 1 and 3 VWD. Qualitative type 2 VWD variants can be attributable to defects in platelet and/or collagen binding [4] . Currently, these patients are classified as type 2M if there is no defect in VWF multimer formation [5] . Platelet binding defects are most prevalent in type 2M VWD, but some collagen binding defects have been reported to affect binding to collagens I and III [6] [7] [8] [9] . Recently, additional variants that affect collagen IV and VI binding have been recognized that may account for up to 5% of type 1 VWD cases in the Zimmermann Program cohort [10, 11] .
Bleeding symptoms may be more prevalent in subjects with VWF variants causing collagen defects, as study subjects with these variants had higher bleeding scores according to the ISTH bleeding assessment tool than similar subjects without collagen binding variants [11, 12] . Given the myriad other genetic and environmental differences in human studies, it is still difficult to prove causality, but human studies suggest that collagen IV binding defects can contribute to clinical bleeding. The most common sequence variant in the VWF A1 domain affecting collagen IV binding was p.Arg1399His, which was present in ⁓ 2% of the Caucasian population [13] . Therefore, we developed a murine model with a VWF variant, p.R1399H (1399H), that has been previously shown to decrease VWF binding to collagen IV (without any effect on binding to collagen III).
The murine and human VWF A1 domain protein sequences at amino acid 1399 are conserved, with both species having an arginine at that position [14, 15] . Previous work on this variant showed that a defect in the VWF-collagen IV interaction could be detected by the use of hydrodynamic tail vein injection, but this method resulted in less than optimal high molecular weight multimers [11] . As high molecular weight multimers are critical for collagen binding, a better model was desired. The 1399H variant was subsequently used to generate a mouse model for in vivo experiments, and is detailed below.
Materials and methods
Generation of a mouse with defective collagen IV binding A targeting vector was constructed (Fig. S1 ) containing the murine C57BL/6J VWF sequence, with the exception of R1399 being replaced by H1399. The construct also contained a neomycin resistance cassette flanked by loxP sites. This was electroporated into JM8.N4 (C57BL/6N) embryonic stem (ES) cells. Neomycin-resistant ES cells that had undergone homologous recombination and carried the p.R1399H VWF allele were identified by PCR and injected into C57BL/6J blastocysts to produce chimeric mice carrying the transgene. After germline transmission of the transgene, the neomycin resistance gene cassette was removed by breeding with Cre-positive mice, and mice with the 1399H mutation were bred with C57BL/6J mice to generate both heterozygous (R1399H) and homozygous (1399H) mice on the C57BL/6J background. Genotyping of mice was performed by PCR analysis of blood-derived genomic DNA. . Multimer distribution was examined by the use of gel electrophoresis [16] . A 2% resolving gel and a 0.8% stacking gel were made by the use of SeaKem HGT(P) agarose (Lonza, Rockland, ME, USA). Samples were run for 16 h at 45 V and 20°C. The gel was transferred to Immobilon-FL (Millipore, Billerica, MA, USA) for 1 h at 4°C. The membrane was blocked for 30 min with Odyssey Blocking Buffer-PBS (Li-Cor, Lincoln, NE, USA). Detection of VWF was performed with a primary antibody (Dako) diluted to 1 lg mL À1 and a secondary fluorescent antibody goat anti-rabbit antibody (IRDye 800CW; Li-Cor) diluted 1 : 20 000.
FVIII activity was measured with the Chromogenix Coatest assay (Diapharma, West Chester, OH, USA).
Tail clip bleeding model
Tail clipping, at a defined length of 3 mm, was performed on anesthetized mice aged 12-16 weeks [17] . Blood from the cut tail was collected in 14 mL of prewarmed (37°C) 0.9% saline until bleeding ceased or 10 min had elapsed, whichever came first. Samples were spun at 1500 r.p.m. for 5 min. The supernatant was aspirated, and the blood pellet was resuspended in 10 mL of dH 2 O to lyse the cells. Blood loss volume was calculated against a C57BL/ 6J standard curve. Blood counts were performed on a retro-orbital blood sample with the Vet abc (SCIL Animal Care Company, Gurnee, IL, USA) to ensure that the baseline hemoglobin level was normal. Curve and sample absorbance were measured on a Nanodrop spectrophotometer (Thermo Scientific) at 416 nm and 575 nm.
Ferric chloride injury model
Mice aged 7-14 weeks were anesthetized with a ketamine/ xylazine cocktail (Midwest Veterinary Supply, Lakeville, MN, USA). The carotid artery was isolated, and a solution of 10% ferric chloride (Sigma Aldrich, St Louis, MO, USA) was applied to the isolated artery with a 1 9 2-mm piece of #1 Whatman filter paper (Whatman International, Maidstone, UK). Clot formation was observed and quantified under ultrasound with the perivascular flow module (T402; Transonic Systems, Ithaca, NY, USA). The assay was allowed to run until 3 min after occlusion and no further signal change, with a 30-min maximum assay time [18] .
Platelet aggregation
Whole blood samples were collected from anesthetized mice aged 14-24 weeks via inferior vena cava (IVC) blood draw into 3.8% sodium citrate. Platelet-rich plasma was obtained by centrifugation (200 9 g for 8 min then 800 9 g for 8 min 9 2) and resuspension in Tyrode's buffer to a final concentration of 1x10 8 platelets. Platelet aggregation in response to type I collagen (BioData Corporation, Horsham, PA, USA) was measured at a final concentration of 75 lg mL À1 , and platelet aggregation in response to murine type IV collagen (Southern Biotech) was measured at a final concentration of 50 lg mL À1 , on a PAP-8E Platelet Aggregation Profiler (BioData Corporation).
VWF-dependent platelet adhesion under flow
Whole blood samples were collected from anesthetized mice aged 16-20 weeks via IVC draw into heparin (1.58 units mL
À1
) and PPACK (0.25 mM). The
VenaFlux system was used to measure quinacrine dihydrochloride-stained platelet adhesion under flow, as previously described [11] . Variable shear rates were tested, including 10, 50 and 90 dyne cm À2 .
Statistics
Data were compared by the use of ANOVA (Kruskal-Wallis) for comparison between multiple genotypes. For individual comparisons, Student's t-test was used for normally distributed data, and the Mann-Whitney test was used for non-normally distributed data. Analysis was performed with GRAPHPAD PRISM version 7 for Windows (GraphPad Software, La Jolla, CA, USA).
Results

Generation of a mouse with defective collagen IV binding
Injection of ES cells with the VWF 1399H variant resulted in C57BL/6J pups that were positive for the 1399H variant. Progeny of colony founders were bred to homozygosity. The offspring were born in normal Mendelian ratios, suggesting that the 1399H variant caused no prenatal or perinatal disadvantage. Table 1 shows the breakdown of offspring from heterozygous breeding pairs, which yielded all expected genotypes: WT (R1399), heterozygous (R1399H), and homozygous (1399H). The expected frequencies of these genotypes is 25%, 50%, and 25%, with the actual frequencies being 22% for WT pups, 53% for heterozygous pups, and 25% for homozygous pups (P = not significant [NS]). Additionally, homozygous females and males showed normal fecundity and fertility when bred with a heterozygous partner. The frequencies of heterozygous and homozygous offspring were 51% and 49%, respectively, with expected ratios of 50% each. These data confirm the lack of deleterious effects on pregnancy and birth for mice carrying the 1399 VWF A1 domain variant. An additional cross was performed between 1399H mice and VWF À/À mice to elicit the phenotype seen in human type 1 VWD subjects, whereby one allele had the 1399H variant and the other allele had a variant that decreased or eliminated VWF expression, resulting in a 
Assays of murine VWF
No differences in VWF:Ag levels were seen when WT, heterozygous and homozygous mice were compared (P = NS), supporting the lack of an effect on VWF expression by the 1399H variant. VWF:CB4 in mice heterozygous for the 1399H variant was found to be $ 65% of the level seen in WT mice, whereas VWF:CB4 in mice homozygous for the 1399H variant was found to be $ 20% of the level seen in WT mice. Mice that were hemizygous for 1399H (1399H 9 VWF À/À parents) also had decreased VWF:CB4 ( $ 30% of that seen in WT mice, identical to 1399H mice). Figure 1 shows the average VWF:CB/VWF:Ag ratio for each genotype. There was a significant difference in VWF:CB4/VWF:Ag (Fig. 1A) between WT mice and all other genotypes (P < 0.0001), as well as between the heterozygous R1399H and homozygous 1399H mice (P < 0.0001), and between the heterozygous R1399H and hemizygous 1399H/ À mice (P < 0.002). No difference, however, was seen in the VWF:CB3/VWF:Ag ratio (Fig. 1B) for any of the genotypes (P = NS). As VWF serves as a carrier protein for FVIII, we also examined FVIII activity, and no difference was seen in FVIII activity when WT mice, heterozygous mice and homozygous 1399H mice were compared (Fig. 1C) .
Tail clip bleeding model
The tail clip bleeding time showed a defect in hemostasis for both heterozygous and homozygous 1399H mice (Fig. 2) . When bleeding time alone was measured, heterozygous 1399H mice bled longer than WT mice (P < 0.01), and homozygous 1399H mice bled longer than heterozygous 1399H mice (P < 0.01). When blood loss was measured, both heterozygous and homozygous 1399H mice had increased blood loss as compared with WT mice (P < 0.01), but, interestingly, no difference was seen in total blood loss between heterozygotes and homozygotes (P = NS). Hemizygous 1399H/ À mice appeared phenotypically similar to the homozygous 1399H mice in this model. VWF À/À mice had both longer bleeding times and higher blood loss than both WT and 1399H mice, in support of the complete lack of VWF causing a more severe phenotype. Table 2 shows the comparison of phenotypes between human and murine 1399H variants.
Ferric chloride injury model
Thrombosis induced by ferric chloride-induced injury was decreased for both heterozygous and homozygous 1399H mice (Fig. 3) . VWF À/À mice had a complete absence of clot formation in this model. WT mice showed faster occlusion than both heterozygous 1399H mice (P < 0.01) and homozygous 1399H mice (P < 0.02). No significant difference was seen in occlusion time, however, between heterozygous and homozygous 1399H mice (P = NS). Although VWF À/À mice had the most prolonged time to occlusion, the presence of at least one 1399H allele did delay thrombosis as compared with WT VWF (Fig. 3) .
Platelet aggregation
As the VWF A1 domain is also critical in platelet binding, we examined platelet aggregation in response to collagen. Figure 4 shows the maximum platelet aggregation induced by either type I or type IV collagen. No difference in platelet aggregation was seen. This most likely reflects aggregation being driven through glycoprotein (GP) VI. The fact that there is normal aggregation even in VWF À/À mice demonstrates that collagen-induced platelet aggregation does not require VWF, or intact VWFcollagen binding.
VWF-dependent platelet adhesion under flow
Because static assays do not fully represent the function of VWF under flow, we also examined VWF-dependent platelet adhesion by using a microfluidic flow-based platform (VenaFlux). Whole blood samples were passed across a chip coated with murine type IV collagen with variable shear rates. Optimal platelet adhesion was seen at a shear of 50 dyne cm À2 . A decrease in platelet adhesion was seen for both R1399H mice and homozygous 1399H mice. Clot formation following platelet adhesion to collagen IV was measured with the area of maximal intensity as a proxy for the area of greatest clot formation (Fig. 5) . At higher and lower shear (90 dyne cm À2 and 10 dyne cm À2 ) adhesion was poor, suggesting that the best adhesion occurs under an intermediate shear rate.
Discussion
VWF-collagen IV interactions are important in hemostasis in our model, at least as indicated by tail bleeding times and blood loss, and are important in thrombus formation, as measured by the use of ferric chloride injury. However, there is no requirement for intact VWF-collagen IV interactions in platelet aggregation, probably because the platelet GPVI receptor engages collagens independently of VWF. As expected, binding to collagen III is preserved in the 1399H model, which may also ameliorate the severity of the bleeding seen in this model. The 1399H homozygous mouse showed an increase in tail bleeding as compared with WT mice, and a similar phenotype was seen with a 1399H hemizygous mouse derived from a cross between 1399H homozygous mice and VWF À/ À mice. This latter model is closer to the VWD phenotype seen in our human subjects; no true 1399H homozygotes were observed among these, but a number of subjects were found to be hemizygous for the 1399H variant, with one allele having 1399H and the other containing a VWF variant that resulted in diminished VWF expression. The lack of homozygous 1399H subjects may be attributable to the fact that these individuals would have completely normal VWF levels in conventional testing with VWF-platelet binding assays and/or collagen I/III binding assays, and therefore may go undiagnosed.
Given the frequency of the 1399H variant, which is present in $ 2% of the Caucasian population [19] , one would expect a number of individuals to be homozygous for the 1399H variant. On the basis of the murine model, it would be expected that either true homozygosity or hemizygosity with a second unexpressed allele could result in bleeding. In the Zimmerman Program, 4% of the type 1 subjects had a collagen IV binding defect, and those with a collagen IV binding defect had increased bleeding as compared with those with normal collagen binding [12] .
Collagen binding defects could also potentially explain some of the variability in patients with low VWF levels. Although the 2008 National Heart, Lung, and Blood Institute guidelines suggested the use of a cut-off of 30 IU dL À1 for type 1 von Willebrand disease [5] , recent evidence from the Irish LoVIC cohort supports the presence of bleeding in individuals with VWF:Ag or ristocetin cofactor activity (platelet binding) between 30 IU dL À1 and 50 IU dL À1 [20] .
Whereas some groups have shown a correlation between bleeding score and VWF level [21] , we and others have shown that elevated bleeding scores can be associated with very mild decreases in VWF levels [12, 20] . Defects outside the VWF locus probably explain some of this variability, but collagen binding defects have also been found, in some 'low-VWF' individuals, to explain their bleeding [6, 8] .
The 1399H murine model explores only the effect of disrupting VWF-collagen IV interactions, Many VWF variants in the A1 domain also affect platelet binding, given that the A1 domain is also the site of VWF binding to platelet GPIb [22] . In the Zimmerman Program, type 2M subjects with isolated platelet binding defects had lower bleeding scores than type 2M subjects with both collagen and platelet binding defects, suggesting an additive effect of VWF defects on bleeding [11] . There are also multiple collagens that bind VWF, and, whereas collagen IV uses the A1 domain, collagens I and III bind VWF via the A3 domain [1] . The preserved ability of the 1399H mice to bind collagen III may account for the relatively mild phenotype as compared with the complete absence of VWF. It is tempting to speculate that VWF interaction with collagen IV is required with deeper endothelial injury to larger vessels, but that other interactions prevail at both very high and very low shear rates.
Collagen may be most important in primary hemostasis, but we did observe decreased thrombosis in response to ferric chloride. Although ferric chloride is not a physiological agonist, this suggests that there may be certain circumstances in which defects in VWF-collagen IV interactions could be protective. There is evidence for collagen IV deposition in atherosclerotic plaques [23] ; one might hypothesize that a defective VWF-collagen IV interaction could potentially reduce the complications of atherosclerotic heart disease. The presence of VWD has been associated with a decreased risk of myocardial infarction and ischemic stroke in human studies, and the 1399H variant could potentially confer similar protection [24] .
Collagen IV is also important in other areas. Megakaryocyte development and proplatelet formation differ according to adhesion to type I or type IV collagen [25] . Mice bred to contain a defect in Col4A1 experience perinatal intracranial hemorrhage [26] . Genetic defects in Col4A1 and COL4A2 have been associated with hemorrhagic stroke [27, 28] . Collagen IV also plays a role in hemostasis by binding FIX [29, 30] . Further studies regarding the alteration of VWF-collagen IV interactions in these areas are ongoing.
One limitation of our model is the lack of spontaneous bleeding, in contrast to the symptoms experienced in typical human patients. Type 1 VWD includes symptoms of easy bruising, epistaxis, and surgical bleeding, and heavy menstrual bleeding and postpartum hemorrhage in women [5] . We did not see any hemorrhage in our mice, but it should be noted that even the VWF À/À mouse does not experience marked spontaneous bleeding [31] . Therefore, this may be a limitation of murine models of VWD. Another limitation is the use of a single VWF variant, p.R1399H, which, in the murine model, did not completely abolish VWF-collagen IV interactions; it is therefore possible that the murine model underestimates the severity of this defect in the human population. We also cannot completely explain the effect of p.R1399H on VWF-GPIb interactions, as it is possible that the change in amino acid allosterically inhibits binding rather than altering the binding site directly. It should also be noted that the mice, although all C56BL/6, were from two slightly variant colonies, and there may have been some genetic drift between the colony containing the 1399H variant and the colony with the VWF À/À allele, and potential differences even between WT and 1399H mice in the same colony. However, we did note that VWF:Ag levels were similar between WT, R1399H and 1399H mice, suggesting that potential background differences did not affect the expression of VWF. Although the 1399H mouse did not show spontaneous bleeding, the increase in bleeding when they were challenged supports a hemostatic defect caused by this variant. Further work remains to be performed in order to explore the effects of complete removal of all VWF-collagen IV interactions on hemostasis, but it does appear that disruption of this interaction has the potential to exacerbate bleeding symptoms. 
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